X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html#:~:text=Voydeya%20(danicopan)%20has%20been%20approved,who%20have%20residual%20haemolytic%20anaemia.
https://www.globenewswire.com/news-release/2024/04/08/2859605/0/en/Onco360-Has-Been-Selected-as-the-Sole-National-Specialty-Pharmacy-Partner-for-Voydeya-danicopan.html
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html#:~:text=Voydeya%20is%20a%20first%2Din,treated%20with%20a%20C5%20inhibitor.
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html
https://www.fiercepharma.com/pharma/astrazeneca-adds-rare-blood-disease-portfolio-world-first-voydeya-approval-japan
https://www.fiercebiotech.com/biotech/ash-novartis-enters-pnh-market-astrazeneca-shows-longer-term-effect-its-latest-contender
https://www.astrazeneca.com/media-centre/press-releases/2023/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients.html
https://www.biospace.com/article/releases/danicopan-alxn2040-add-on-to-ultomiris-ravulizumab-cwvz-or-soliris-eculizumab-met-primary-endpoint-in-alpha-phase-iii-trial-for-patients-with-paroxysmal-nocturnal-hemoglobinuria/?s=69
Market Place
Share 
